Tinsley R, Eriksson P
Department of Clinical Neuroscience, Sahlgrenska University Hospital, Göteborg, Sweden.
Acta Neurol Scand. 2004 Jan;109(1):1-8. doi: 10.1046/j.1600-0404.2003.00240.x.
Recent advances have increased our molecular understanding of the central nervous system (CNS), in both health and disease. In order to realize the clinical benefits of these findings, new molecular-based therapies need to be developed, such as CNS gene therapy. Although the field has suffered setbacks, it remains an attractive technology for providing new therapies in the post-genomic world. The development of new vectors, and their extensive application in animal models of CNS disease, provides evidence suggesting that gene therapy will eventually become an accepted clinical option. In fact, the first gene therapy clinical trial for Parkinson's disease has recently begun. This review discusses how gene therapy has been applied in animal models, and how it may be used to repair the damage caused by CNS diseases and trauma in human beings. Furthermore, it explores how such treatments may be combined with, and augment, more conventional therapeutic approaches.
近年来的进展加深了我们对中枢神经系统(CNS)在健康和疾病状态下的分子层面理解。为了将这些研究成果转化为临床效益,需要开发新的基于分子的疗法,比如中枢神经系统基因疗法。尽管该领域遭遇过挫折,但在这个后基因组时代,它仍是一种颇具吸引力的提供新疗法的技术。新型载体的研发及其在中枢神经系统疾病动物模型中的广泛应用,为基因疗法最终会成为被认可的临床选择提供了证据。事实上,首个针对帕金森病的基因疗法临床试验最近已经启动。这篇综述讨论了基因疗法如何应用于动物模型,以及它如何用于修复人类中枢神经系统疾病和创伤造成的损伤。此外,还探讨了此类治疗如何与更传统的治疗方法相结合并增强其效果。